ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial

Reuters

2025/11/12

ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial

ProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582887375"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582887375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582887375?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582887375","market":"us","top_or_hot":-1,"title":"ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-12 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMN","symbol_name":"ProMIS Neurosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9tGKFT:1","article_id":"2582887375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582887375","pubTimestamp":1762949155,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMN":"ProMIS Neurosciences Inc","BK4139":"生物科技"},"translate_title":"ProMIS Neurosciences报告现金状况增加以及阿尔茨海默病试验取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    \n\nProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}